Twist Bioscience Retains Leading Law Firm Quinn Emanuel to Combat Lawsuit Filed by Agilent Technologies

Download PDF
SAN FRANCISCO, Calif. – May 19, 2016 — Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it has retained the leading trial law firm of Quinn Emanuel Urquhart & Sullivan LLP to defend against the February 3, 2016 lawsuit filed by Agilent Technologies.
Twist Bioscience was founded by Bill Banyai, Ph.D., Emily Leproust, Ph.D., and Bill Peck, Ph.D. approximately three years ago based on a proprietary method of synthesizing DNA on a 10,000-well silicon chip rather than using a standard 96-well plate.  Quinn Emanuel is jointly representing Twist Bioscience and its chief executive officer, Emily Leproust.
Quinn Emanuel is a business litigation firm with more than 700 lawyers in 18 offices worldwide and is the largest law firm in the world devoted solely to business litigation and arbitration.  The firm’s lawyers have tried more than 2,500 cases, winning 88% of them.  Quinn Emanuel is routinely recognized for its excellence by the legal press, having been named the “US Law Firm of the Year” three times by Legal Business, the top IP litigation firm by The American Lawyer, and one of the four “most feared” law firms by General Counsels at Fortune 500 companies.  Quinn Emanuel’s life sciences partners represent pharmaceutical, biotechnology, medical device, and other life sciences companies from around the world. Further information about the firm is available at
“We firmly believe that Agilent’s allegations are baseless and without merit, and we look forward to prevailing in court on behalf of Twist Bioscience and its CEO,” said Kevin P.B. Johnson, partner of Quinn Emanuel.
About Twist Bioscience Corporation
At Twist Bioscience, our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production, which in turn, expedites the design, build, test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics, biodetection and data storage. For more information, please visit Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at


Twist Bioscience Contacts: